2025 International Antibody Validation Meeting: First Look at Programme
5
Min Read
In this blog:
- Get a taster of the talks at this year's AbVal meeting
- Where can you learn more about the speakers?
- Why attend?
We are thrilled to release the preliminary programme for the 2025 International Antibody Validation meeting, taking place from 9th–11th September at the University of Bath, UK.
With over $1 billion spent annually on research antibodies and up to 50% not working as expected, antibody validation is an essential part of improving reproducibility in life science [1,2].
Running since 2014, the Antibody Validation meeting fosters in-depth discussions and collaboration to help drive progress and discuss best practice in this field.
With scientific support from AstraZeneca and co-organised with the University of Bath, this focused event brings together scientific leaders across the globe from academia, biotech, biopharma, and reagent supplier companies to tackle the pressing challenge of antibody validation.
This year’s programme features 22 confirmed speakers from leading research institutions, supplier companies and independent organisations, including the Michael J Fox Foundation for Parkinson’s Research, Regeneron, GSK, Novartis, the University of California, Davis and many more.
Talks from the 2025 programme include:
- Andrea Radtke, Leica Microsystems: It takes a community: Impact of HuBMAP and grassroots efforts to characterize antibodies for spatial biology applications
- Carl Laflamme, Neuro-SGC, YCharOS initiative: Antibody Validation as a Scientific Discipline: Lessons and Challenges from YCharOS
- Ulf Landegren, Uppsala University: Minimizing antibody cross-reactivity and revealing dynamic protein activity states via dual recognition in solution and in situ
- Deborah Moshinsky, Institute for Protein Innovation (IPI): Systematic Antibody Validation for Community Distribution Using High-Throughput Biophysical and Functional Testing
- Andrew Bradbury, Specifica, an IQVIA business: The AIntibody challenge: an update on the use of AI/ML in antibody discovery
‘’We’re really excited to welcome delegates from all over the world to CiteAb’s home city of Bath this September. The AbVal meeting has always been a great event for lively discussion and the sharing of insight, experience and data from key stakeholders – all of which is essential to drive progress in antibody validation and experimental reproducibility. This year’s meeting is shaping up to be one of the most exciting yet, with a fantastic array of speakers confirmed.”
Dr Andrew Chalmers, CEO of CiteAb
You can find out more about what to expect from AbVal 2025 (such as a poster session and a meeting dinner) here.
We hope to see you in Bath this September!
